Zyn, But With Weed: The Pouch Craze Hits The Cannabis Industry https://t.co/v5DFZ8JNXQ https://t.co/v5DFZ8JNXQ ...

Core Insights - Altria Group, Inc. is focusing on its oral nicotine pouch brand on! to enhance its presence in the smoke-free category, achieving over 18% shipment growth in Q1 2025 and increasing its market share to 8.8% [1][7] - The brand on! has captured 17.9% of the nicotine pouch segment, reflecting its strength despite competitive pressures and rising prices [1][7] - Strategic investments, particularly the "It's On!" marketing campaign, have significantly boosted consumer awareness, now exceeding 60% [2] Company Performance - Altria's shipment growth for on! is attributed to effective marketing and the upcoming launch of on! PLUS, targeting a key demographic for expansion [2][3] - The company is well-positioned for future growth through disciplined pricing strategies, brand equity, and planned innovations [3] - Altria's stock has gained 1.5% over the past month, contrasting with a 0.2% decline in the industry [6] Peer Comparison - Philip Morris continues to lead the nicotine pouch market with ZYN, reporting a 63% year-over-year increase in shipments, reaching over 200 million cans in Q1 2025 [4] - Turning Point Brands is also gaining traction with its modern oral products, forecasting nearly 10x year-over-year growth and expanding its sales force [5] Valuation and Earnings Estimates - Altria trades at a forward price-to-earnings ratio of 10.84X, below the industry average of 15.11X [8] - The Zacks Consensus Estimate indicates year-over-year earnings growth of 4.9% for 2025 and 3.3% for 2026 [9]

Turning Point Brands (TPB) Q1 2025 Earnings Call May 07, 2025 09:30 AM ET Company Participants Andrew Flynn - CFOGraham Purdy - CEO, President & DirectorSummer Frein - Chief Revenue OfficerAaron Grey - Managing Director, Head of Consumer ResearchIan Zaffino - Managing Director Conference Call Participants Eric Des Lauriers - Senior Research AnalystNick Anderson - Director & Research Analyst Operator Good morning, and welcome to the Turning Point Brand Q1 twenty twenty five Conference Call. All participants ...

Financial Data and Key Metrics Changes - Revenue increased by 28% to $106.4 million for Q1 2025, with adjusted EBITDA rising by 12% to $27.7 million [4][13] - Gross margin was 56%, down 220 basis points year over year but flat sequentially [13] - Free cash flow for the quarter was $12.4 million, with capital expenditures of $2.2 million [16] Business Line Data and Key Metrics Changes - Modern Oral revenue reached $22.3 million, with sales increasing nearly 10 times year over year [5][16] - Stoker's revenue increased by 63% to $59.2 million, with MST portfolio net sales growing by 10% to $26.3 million [7][15] - Zig Zag sales increased by 1% year over year to $47.3 million, with gross profit decreasing by 7.2% compared to the prior year [14] Market Data and Key Metrics Changes - The company anticipates the modern oral category will exceed $5 billion in manufacturers' revenue by the end of the decade [5] - The company aims for a long-term target of double-digit market share in the modern oral space [6] Company Strategy and Development Direction - The company is increasing full-year consolidated nicotine pouch sales guidance to a range of $80 million to $95 million from $60 million to $80 million [5][17] - Key initiatives include reallocating sales and marketing resources, increasing sales force headcount, and improving online presence [6][10] - The company is exploring U.S. manufacturing to improve profitability and mitigate supply chain risks [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of white nicotine pouch brands and the overall modern oral category [5][6] - The company is focused on building brands for the long term and executing against an omnichannel plan [11][12] - Management acknowledged potential headwinds from tariffs and foreign exchange impacts on the Zig Zag segment [17] Other Important Information - The company reaffirmed its previously announced 2025 adjusted EBITDA guidance of $108 million to $113 million [5][17] - Budgeted capital expenditures for 2025 are projected to be between $4 million to $5 million, excluding modern oral business projects [17] Q&A Session Summary Question: Comments on distribution gains in Modern Oral and rollout expectations for ALP - Management noted strong traction with retailers and plans for rollouts and enhancements later in the year [22][23] Question: Capacity to produce nicotine pouches at current facilities - Management confirmed adequate supply and ongoing exploration of onshoring production options [26] Question: Timing impact on pouch shipments and brand awareness for ALP - Management indicated that ALP's rollout is focused on online direct-to-consumer channels and is seeing good brand awareness [30][32] Question: Stoker segment gross margin performance - Management stated that pouch margins are within previously discussed ranges and are performing well [35] Question: Advertising regulations for nicotine pouches - Management acknowledged more flexibility in advertising compared to traditional tobacco products but emphasized responsible marketing [44] Question: Timing of PMTA applications amid FDA changes - Management indicated uncertainty regarding timing due to changes in government but continues to monitor the situation [46]

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch MarketApril 28, 2025 9:36 AM EDT | Source: ArcStone US Corp.New York, New York, Dallas, Texas, and Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a leading cross-border financial services firm, today announced the publication of an industry report on the rapidly emerging oral stimulant pouch market — a multi-billio ...

DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokele ...

Turning Point Brands, Inc. (NYSE:TPB) Q4 2024 Earnings Conference Call March 6, 2025 10:00 AM ET Company Participants Andrew Flynn - Chief Financial Officer Graham A. Purdy - President and Chief Executive Officer Summer Frein - Chief Marketing Officer Conference Call Participants Eric Des Lauriers - Craig Hallum Capital Group Ian Zaffino - Oppenheimer Nick Anderson - ROTH Capital Partners Aaron Grey - Alliance Global Partners Operator Thank you for standing by. My name is Kathleen, and I will be your confer ...